Key Highlights: Global first “immuno + anti-vascular” bispecific antibody approved: ivonescimab for EGFR-TKI resistant nsq-NSCLC. Phase III HARMONi study topline data expected mid-2025 (FDA FTD). ivonescimab outperforms pembrolizumab in Phase III study for first-line PD-L1+ NSCLC: mPFS…

In Phase 2 ALPACA results, lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor, with some patients sustaining reductions for nearly 1.5 years These data were presented at the American College of Cardiology 2025 Scientific Sessions and…

BEIJING, March 30, 2025 /PRNewswire/ — Government service halls across many regions in China have established dedicated feedback windows for handling unfinished work. What is such window? Out of the curiosity, the Global Times recently visited the government service center in Anji…

GALWAY, Ireland and CHICAGO, March 30, 2025 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut™ transcatheter aortic valve…

LOS ANGELES, March 30, 2025 /PRNewswire/ — Congress Majority PAC is now running some strongly worded vote Democrat video ads in deep-red districts in Florida that are holding special elections for two House seats on April 1st. One ad says, “Trump’s extremism is reckless, and his tariffs…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.